Cart
sales@molnova.com
AZD8835
CAS No. 1620576-64-8
AZD8835 ( AZD-8835 )
Catalog No. M12383 CAS No. 1620576-64-8
AZD8835 (AZD-8835) is a potent, selective inhibitor of PI3Kα and PI3Kδ with IC50 of 6.2 and 5.7 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 40 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 95 | In Stock |
|
| 25MG | 178 | In Stock |
|
| 50MG | 260 | In Stock |
|
| 100MG | 447 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAZD8835
-
NoteResearch use only, not for human use.
-
Brief DescriptionAZD8835 (AZD-8835) is a potent, selective inhibitor of PI3Kα and PI3Kδ with IC50 of 6.2 and 5.7 nM.
-
DescriptionAZD8835 (AZD-8835) is a potent, selective inhibitor of PI3Kα and PI3Kδ with IC50 of 6.2 and 5.7 nM, 15-fold and >100-fold selectivity over PI3Kγ and PI3Kβ; also potently inhibits PI3Kα mutants E545K and H1047R with IC50 of 6 nM; preferentially inhibits growth in cells with mutant PIK3CA status inhibits AKT phosphorylation with IC50 of 58 nM in PIK3CA mutant human breast ductal carcinoma BT474 cell line; suppresses tumour growth (93% tumour growth inhibition) in murine H1047R PI3Kα mutated SKOV-3 xenograft tumour model (25mg/kg b.i.d).Breast Cancer Phase 1 Discontinued
-
SynonymsAZD-8835
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3Kα;PI3Kβ;PI3Kγ;PI3Kδ
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number1620576-64-8
-
Formula Weight469.54
-
Molecular FormulaC22H31N9O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 16 mg/mL
-
SMILESO=C(N1CCC(C2=NN(CC)C(C3=NC(C4=NN=C(C(C)(C)C)O4)=C(N)N=C3)=N2)CC1)CCO
-
Chemical Name1-Propanone, 1-[4-[5-[5-amino-6-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-2-pyrazinyl]-1-ethyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl]-3-hydroxy-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Barlaam B, et al. Bioorg Med Chem Lett. 2015 Nov 15;25(22):5155-62.
2. Hudson K, et al. Mol Cancer Ther. 2016 May;15(5):877-89.
3. Lynch JT, et al. Oncotarget. 2016 Apr 19;7(16):22128-39.
4. Maynard J, et al. PLoS One. 2017 Aug 14;12(8):e0183048.
2. Hudson K, et al. Mol Cancer Ther. 2016 May;15(5):877-89.
3. Lynch JT, et al. Oncotarget. 2016 Apr 19;7(16):22128-39.
4. Maynard J, et al. PLoS One. 2017 Aug 14;12(8):e0183048.
molnova catalog
related products
-
NVP-BGT226
NVP-BGT226 (BGT226) is a potent, dual PI3K/mTOR inhibitor with a preference for PI3Kα and mTOR.
-
PI3K/mTOR Inhibitor-...
PI3K/mTOR Inhibitor-2 is a potent pan inhibitor of PI3K and mTOR with IC50s of 3.4, 34, 16,1 and 4.7 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR. PI3K/mTOR Inhibitor-2 has antitumor activity.
-
GSK-2636771
GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines. Phase 1/2a.
